


# MONDAY MORNING ONCOLOGY UPDATE



## ROSWELL PARK CANCER INSTITUTE AMERICA'S FIRST CANCER CENTER

News briefs from Roswell Park for Western New York physicians • October 29, 2001

### CALENDAR

#### Surgical Grand Rounds

**October 31**

(7-8am)

Treatment of Stage I/II Breast Cancer: Evidence Based Guidelines

**Stephen B. Edge, MD,** Chief, Breast Surgery and Acting Chair, Department of Surgery, RPCI

Cafeteria Rooms B&C  
(716) 845-5916

#### Breast Cancer Conference

**November 1**

(7:30-8:30 am)

Case/Clinical Presentation

Johnson Conference Room, Hospital  
(716) 845-5789

#### Medical Grand Rounds

**November 2**

(8:30-9:30am)

Treatment of Nonsmall Cell Lung Cancer

**Mark Socinski, MD** University of North Carolina, Chapel Hill, NC

Research Studies Center  
(716) 845-8707



Physician Information  
1-800-ROSWELL

### Redbook Recognition

Two RPCI physicians are listed among the top breast cancer doctors in America in the October issue of *Redbook* Magazine.

Stephen B. Edge, MD, Department of Surgery, and Ellis Levine, MD, Department of Medicine are among 355 physicians on the magazine's "Exclusive List: The Breast Cancer Specialist's Rated the Best by Their Peers."

### Stop Smoking Clinic

A three-session Stop Smoking Clinic will be held **Mondays, November 5, 12 and 19, from 6:30 to 8 pm**, at the Research Studies Center, RPCI, located at the corner of Elm and Carlton Streets.

Participants receive a stop smoking booklet, and information on withdrawal symptoms, nicotine skin patches, weight control methods and tips on how to remain smoke-free. The clinic fee of \$10 is covered by Independent Health, Univera Healthcare, Blue Cross & Blue Shield of Western New York and Community Blue. **Your patients can register by calling (716) 845-8046.** If your patients are unable to attend the clinic, smoking cessation information and materials may be obtained by calling the New York State Smokers Quit Line at 1-888-609-6292.

### Ovarian Cancer Trials at RPCI

Two new ovarian cancer prevention trials are accruing patients at RPCI. Initially, women in the Gilda Radner Familial Ovarian Cancer Registry were invited to participate, but any woman with an increased risk of ovarian cancer (either due to family history or previous use of fertility medication) may be eligible. Your patients may contact 1-877-ASK-RPCI (1-877-275-7724) for more information.

The first is a chemoprevention trial offered through the Gynecologic Oncology Group (GOG). It involves the use of a potential ovarian cancer preventive drug called fenretinide. Preliminary data indicate that fenretinide may delay or perhaps prevent the onset of ovarian cancer. The trial is open to women with a family history of ovarian cancer who are considering having their ovaries removed as a means to lower their risk for ovarian cancer.

The second is an ovarian cancer screening study, sponsored by the National Ovarian Cancer Screening Program, that may improve early detection and diagnosis of ovarian cancer. It involves a blood test to evaluate levels of CA125 as well as novel, potential biochemical markers, ultrasound examination of the ovaries, and a new test that we feel could be considered an "ovarian pap test." In the "ovarian pap test," ovarian surface epithelial cells are collected by laparoscopy and examined cytologically for potential markers of early disease. We believe that this study may help to accurately detect pre-cancerous changes in the ovary or possibly detect ovarian cancer at an early stage.

### Center of Excellence

RPCI has been named a Center of Excellence in the research, diagnosis, and treatment of myelodysplastic syndromes by the Myelodysplastic Syndromes (MDS) Foundation, a non-profit, international scientific organization focusing on clinical research and education in the myelodysplastic syndromes for physicians and patients. In granting the citation, the MDS Foundation acknowledged RPCI's research in microassay analysis of MDS, clinical trials of novel agents, and quality of life issues.

RPCI is one of 64 university-based hospitals worldwide designated as Centers of Excellence by the MDS Foundation. The MDS program leader at RPCI is James L. Slack, MD, Department of Medicine.